PTI-125 Reduces Neurodegeneration After 28 Days of Treatment, Data Show
PTI-125, Cassava Sciences’ lead therapeutic candidate for the treatment of Alzheimer’s disease, significantly reduced the levels of disease biomarkers, brain inflammation, and neurodegeneration after 28 days of treatment, top-line data from a Phase 2 trial show. “Based on these encouraging biomarker results, this new treatment could be…